+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Rechargeable SCS, Non-Rechargeable SCS), By Application (Hospitals, Ambulatory Surgery Centers, Others), By Patient Group (Patients with Failed Back Surgery Syndrome (FBSS), Patients with Complex Regional Pain Syndrome (CRPS), Patients with Other Chronic Pain Conditions), By Technology (Traditional Low-Frequency SCS, High-Frequency SCS (including 10 kHz), Burst Stimulation Technology), By Implantation Procedure (Percutaneous Implantation, Surgical Laminectomy/Laminotomy, Paddle Lead Implantation), and Regional Forecast, 2026-2034
The global spinal cord stimulation devices market was valued at USD 2.76 billion in 2025 and is estimated at USD 2.95 billion in 2026. The market is projected to reach USD 5.05 billion by 2034, representing a 6.9% CAGR during 2026–2034.
Spinal cord stimulation systems are implantable neuromodulation devices that deliver electrical stimulation through epidural leads to modify chronic pain signaling. Commercial systems include an implanted pulse generator, one or more leads, external programming equipment and patient controls. The therapy is used after appropriate patient selection when persistent neuropathic or other approved chronic pain has not been adequately managed with less invasive approaches.
Underlying demand remains substantial. CDC reported that 24.3% of U.S. adults experienced chronic pain in 2023 and 8.5% experienced high-impact chronic pain that frequently limited life or work activities. SCS addresses only a selected fraction of this population, but the prevalence of persistent pain sustains referral into multidisciplinary pain programs and supports continued investment in device-based non-pharmacologic treatment options.
Technology competition has shifted from basic tonic stimulation toward differentiated waveforms, high-frequency therapy, sensing, closed-loop control, automated programming, smaller implantable pulse generators and improved MRI access. Saluda Medical received U.S. FDA approval for its EVA automated programming platform and expanded the technology into Europe in 2026, while Abbott received a 2026 labeling change expanding MR-conditional positioning for Eterna and Proclaim SCS systems. These developments place software, sensing and lifecycle usability alongside stimulation efficacy as key purchasing factors.
Source: CDC chronic-pain data; NICE TA159; FDA Abbott SCS approval; Saluda EVA FDA approval; FDA 2026 Abbott MR labeling.
The study defines the global spinal cord stimulation devices market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Rechargeable SCS; Non-Rechargeable SCS |
| By Application | Hospitals; Ambulatory Surgery Centers; Others |
| By Patient Group | Patients with Failed Back Surgery Syndrome (FBSS); Patients with Complex Regional Pain Syndrome (CRPS); Patients with Other Chronic Pain Conditions |
| By Technology | Traditional Low-Frequency SCS; High-Frequency SCS (including 10 kHz); Burst Stimulation Technology |
| By Implantation Procedure | Percutaneous Implantation; Surgical Laminectomy/Laminotomy; Paddle Lead Implantation |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; France; Italy; China; Japan; India; South Korea; Australia; Brazil; GCC countries; South Africa and other major markets |
| Key Market Players | Medtronic plc; Boston Scientific Corporation; Abbott; Globus Medical (Nevro); Saluda Medical; Nalu Medical |
The market includes implantable spinal cord stimulation systems used for chronic-pain neuromodulation, including implantable pulse generators, SCS leads and the device-specific programming and patient-control components sold as part of the therapy platform. Revenue is attributed to SCS systems and directly associated implant hardware within the syndicated device scope.
Peripheral nerve stimulation, dorsal root ganglion stimulation when sold as a distinct therapy category, intrathecal drug-delivery pumps, deep-brain stimulation and non-implantable electrical-stimulation devices are outside the core SCS market boundary unless discussed as competing or adjacent technologies.
CDC reported that 24.3% of U.S. adults had chronic pain in 2023 and 8.5% had high-impact chronic pain. SCS is reserved for selected patients, but the scale of persistent pain creates a durable population entering specialist evaluation after medication, rehabilitation, injections or prior surgery fail to provide adequate control.
SCS is not a first-line device therapy. NICE recommends SCS for selected adults with chronic neuropathic pain after at least six months of conventional management, a successful trial and multidisciplinary assessment. This staged pathway improves patient selection but adds clinical visits, trial-device costs and potential drop-off before permanent implantation.
Rechargeable systems are favored for long-duration therapy and advanced stimulation patterns that can require greater energy. Their value proposition is reduced need for battery-depletion replacement surgery, while non-rechargeable systems remain relevant for patients who prefer lower maintenance or have lower expected energy use.
Lead migration, infection, hardware malfunction and loss of therapeutic benefit can require reprogramming, revision or explantation. These risks make implant technique, lead design, infection prevention, post-implant monitoring and long-term manufacturer support important in both clinical outcomes and total cost of care.
SCS historically requires iterative programming to identify effective stimulation settings. Saluda Medical’s EVA platform automates parts of the programming process using neural-response sensing, illustrating how software can shift value from manual parameter adjustment toward biomarker-informed personalization and more efficient clinic workflows.
Source: CDC NCHS; NICE TA159; Saluda EVA.
Closed-loop systems measure evoked compound action potentials and use the neural response to maintain stimulation near prescribed levels. This changes the competitive basis from simply delivering a waveform to sensing how the spinal cord responds and adapting therapy accordingly.
Saluda Medical announced FDA approval in January 2025 and full U.S. commercial launch in July 2025 for EVA, which automates manual programming steps and analyzes neural responses. The company expanded regulatory access to Europe and Australia in January 2026, showing that programming workflow is becoming a commercial platform feature.
High-frequency stimulation and burst programming reduce reliance on conventional paresthesia-based tonic therapy and allow physicians to match therapy to different pain patterns and patient preferences. These technologies support premium device differentiation and create continuing demand for clinical evidence comparing durable outcomes.
Patients with implanted SCS systems may require MRI during years of therapy. FDA approved a 2026 labeling update for Abbott Eterna and Proclaim systems that expanded MR-conditional labeling to include prone positioning, illustrating how imaging compatibility can influence device value after implantation.
Globus Medical completed its acquisition of Nevro on April 3, 2025, bringing Nevro’s high-frequency SCS technology into a larger musculoskeletal technology organization. The transaction changes the competitive structure by combining neuromodulation assets with Globus Medical’s broader commercial infrastructure.
Source: Saluda U.S. EVA launch; Saluda European approval; FDA Abbott MR labeling; Globus Medical / SEC.
SCS platforms are increasingly differentiated by waveform, sensing, energy management, lead strategy, programming workflow and compatibility with future diagnostic imaging rather than by the implantable pulse generator alone.
Traditional SCS uses lower-frequency pulses and often produces paresthesia overlapping the painful area. It remains clinically established and provides a benchmark against newer stimulation strategies.
High-frequency systems deliver stimulation at frequencies that can avoid traditional tingling sensations. The approach has become a major competitive technology for chronic back and leg pain.
Closed-loop devices measure neural responses and adjust stimulation to account for changes in posture and electrode-to-cord distance, supporting more consistent dose delivery.
Automated programming, clinician software and remote-capable digital ecosystems can reduce adjustment burden, standardize follow-up and make software updates an increasingly important part of device lifecycle value.
Source: NICE SCS technology; Saluda EVA.
Type segmentation reflects how implanted pulse generators manage energy over the long treatment horizon. Rechargeable and non-rechargeable systems address different patient preferences, energy requirements and replacement trade-offs.
Rechargeable SCS is the leading type. These systems are well suited to patients expected to use stimulation for many years and to therapy settings with higher energy demand. The trade-off is the need for regular charging and patient engagement with the power-management routine.
Non-rechargeable systems remove the ongoing charging requirement and can simplify daily device maintenance. Their commercial fit is strongest where expected battery life is sufficient for the patient’s stimulation needs, although eventual battery depletion requires implantable pulse-generator replacement.
Application segmentation is led by hospitals because permanent SCS implantation requires specialist surgical and pain-management capability, although selected procedures and follow-up can move into ambulatory environments.
Hospitals remain the primary application setting for complex SCS programs because they bring together pain medicine, anesthesia, neurosurgery or spine surgery, imaging, infection control and post-operative support. Major academic centers also drive clinical research and adoption of new waveforms and sensing technologies.
Ambulatory surgery centers can support selected trial and implantation procedures where patient risk, payer rules and facility capability permit. Growth is linked to the broader migration of suitable interventional pain procedures into lower-cost outpatient settings.
Other settings include specialized pain clinics and integrated neuromodulation centers involved in assessment, programming and longitudinal follow-up. The permanent implant itself remains dependent on appropriately equipped procedural environments.
Patient-group segmentation reflects the chronic-pain conditions represented in the report scope. Successful SCS depends on careful selection because pain mechanism, prior surgery, psychological factors and response during trial stimulation can all affect outcomes.
Patients with persistent neuropathic back or leg pain after spine surgery remain a core SCS population. The long clinical history of SCS in post-surgical pain supports physician familiarity and established referral pathways.
CRPS is a severe chronic pain condition in which neuromodulation may be considered after conventional management fails. Use is more selective and depends on local clinical guidance, evidence interpretation and payer policy.
Approved indications have broadened across manufacturers and jurisdictions to include additional chronic intractable pain populations. Expansion depends on robust clinical evidence, regulatory labeling and reimbursement rather than off-label demand alone.
Technology competition is centered on how stimulation is delivered and controlled. No single waveform is optimal for every patient, so manufacturers are building platforms capable of differentiated or multiple programming approaches.
Traditional low-frequency tonic stimulation remains an established therapy with a long clinical evidence base. It relies on conventional pulse patterns and often produces paresthesia that is mapped to the painful region.
High-frequency SCS is a major growth technology because it provides paresthesia-free therapy and has built a distinct clinical position in chronic back and leg pain. Globus Medical’s acquisition of Nevro brought a recognized high-frequency portfolio into its musculoskeletal business.
Burst stimulation delivers grouped pulses intended to provide pain relief with reduced or absent paresthesia for many patients. It expands physician programming choice and supports competition on therapy flexibility rather than a single fixed waveform.
Implantation technique affects invasiveness, lead stability, trial strategy and the surgical resources required. Percutaneous approaches dominate trial workflows, while paddle leads require a more involved surgical approach.
Percutaneous leads can be introduced through a needle or small access route and are widely used for temporary SCS trials and permanent cylindrical-lead systems. Lower procedural invasiveness and the ability to test therapy before a permanent implant support broad use.
Surgical access is used when paddle leads or specific anatomic considerations require direct epidural placement. The approach can provide stable lead positioning but needs operating-room resources and a more invasive procedure.
Paddle leads provide broad electrode arrays and can reduce migration in selected cases, but implantation generally requires laminotomy or laminectomy. Their use is concentrated in patients where surgical placement is justified by expected therapy requirements.
Regional market development depends on specialist pain infrastructure, reimbursement, regulatory approvals, implantation training and patient awareness. North America is the largest market, Europe has established reimbursement in selected systems, and Asia-Pacific offers long-term expansion as access to neuromodulation grows.
The United States anchors global SCS commercialization through a dense pain-management and hospital network, broad manufacturer presence and active product regulation. High chronic-pain prevalence supports the referral base, while FDA approvals and frequent platform updates accelerate adoption of new stimulation and programming technologies.
Europe has long-standing clinical use of SCS, but access varies by national reimbursement and health-technology assessment. NICE guidance in the United Kingdom illustrates the emphasis on multidisciplinary selection, successful trial stimulation and cost-aware device choice.
Asia-Pacific offers growth through rising specialist pain-management capability and investment in advanced neuromodulation, although reimbursement and physician access are uneven. Japan and Australia are established medical-device markets, while China, India and Southeast Asia offer larger but more variable long-term opportunities.
Latin American demand is concentrated in private and tertiary-care centers with specialist pain programs. Import costs, payer coverage and the number of trained implanting physicians limit broad penetration, creating a market focused on higher-income urban centers.
Adoption remains selective, with higher-value opportunities in Gulf tertiary hospitals and specialty pain centers. Limited reimbursement and specialist infrastructure constrain use across many lower-resource markets, favoring targeted rather than mass adoption.
Source: CDC NCHS; NICE TA159; Saluda Europe.
SCS adoption is strongly shaped by device regulation and payer rules because therapy requires an invasive trial and permanent implant, specialist follow-up and long-term device management. Clear indications and reimbursement criteria can materially affect the number of patients progressing from referral to implant.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| U.S. FDA PMA pathway | Implantable SCS systems are high-risk medical devices regulated through premarket approval and subsequent PMA supplements. | Creates a high evidence and quality threshold while allowing established platforms to evolve through approved labeling and design changes. |
| NICE TA159 | NICE recommends SCS for selected adults with chronic neuropathic pain after at least six months of appropriate conventional management, successful trial stimulation and multidisciplinary assessment. | Provides a structured access pathway and emphasizes both clinical selection and device cost. |
| MR-conditional labeling | FDA approved a 2026 labeling change for Abbott Eterna and Proclaim systems expanding MR-conditional positioning. | Improves long-term usability for implanted patients who may need future MRI examinations. |
| Programming technology approvals | Saluda received U.S. approval for EVA and CE certification in Europe with recognition in Australia. | Shows that software and sensing updates can become regulated commercial differentiators alongside implant hardware. |
Source: FDA Abbott SCS; FDA Abbott MR update; NICE TA159; Saluda EVA.
SCS is a concentrated neuromodulation market led by large medical-device companies with established pain franchises, clinical evidence and global field-support organizations. Competition increasingly occurs at the therapy-system level: waveform portfolio, sensing, programming burden, charging experience, MRI compatibility, lead options, clinical data and physician support all influence share.
Medtronic, Boston Scientific and Abbott combine broad implant portfolios with large commercial organizations and long-term clinical presence. Their installed bases create recurring replacement, lead and programming opportunities.
Globus Medical completed its acquisition of Nevro in April 2025. The transaction gives Globus access to Nevro’s differentiated high-frequency SCS technology and changes the competitive structure of the pain neuromodulation segment.
Saluda differentiates through ECAP-based closed-loop therapy and automated programming. U.S. and European regulatory expansion for EVA demonstrates how sensing and software can create a distinct competitive position.
Source: Globus SEC filing; Globus 2025 annual filing; Saluda EVA.
January 2026: FDA approved a labeling change for Abbott Eterna and Proclaim SCS systems that expanded MR-conditional labeling to include prone positioning and updated radiofrequency-heating conditions. MRI access is an important lifecycle consideration for patients living with implanted systems.
January 2026: Saluda Medical received CE certification for EVA Sensing Technology in Europe, with recognition in Australia, following U.S. FDA approval. The expansion extends automated, neural-response-based programming into additional commercial markets.
July 2025: Saluda Medical announced the full U.S. launch of EVA for the Evoke SmartLoop system, advancing automated programming as a practical commercial feature rather than a research-only capability.
April 2025: Globus Medical completed its acquisition of Nevro, making Nevro a wholly owned subsidiary and adding differentiated high-frequency SCS technology to Globus Medical’s portfolio.
Source: FDA PMA supplement; Saluda European approval; Saluda U.S. launch; Globus SEC filing.
The global spinal cord stimulation devices market market is projected to grow from USD 2.95 billion in 2026 to USD 5.05 billion by 2034, at a 6.9% CAGR during 2026–2034. Growth is expected to come from continued chronic-pain demand, broader use of rechargeable systems, closed-loop sensing, automated programming and high-frequency or burst therapy. Market expansion will remain moderated by invasive-procedure economics, patient-selection requirements, revision risk and uneven reimbursement outside mature neuromodulation markets.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Chronic-pain referral base | CDC reports substantial chronic and high-impact chronic pain prevalence in U.S. adults. | Supports a durable pool of patients entering specialist pain evaluation, although only a subset is appropriate for SCS. |
| Closed-loop & automation | Commercial SCS platforms are adding ECAP sensing and automated programming. | Can improve therapy consistency and reduce programming burden, supporting premium differentiation. |
| Rechargeable system adoption | Long-term therapy and energy-intensive waveforms favor rechargeable implants for many patients. | Supports replacement and upgrade demand for smaller and more efficient rechargeable platforms. |
| MRI compatibility | Patients with long-duration implants may require future diagnostic imaging. | Makes MR-conditional labeling and broader scanning conditions an important lifecycle feature. |
| Reimbursement discipline | Guidance and payer criteria require appropriate selection, trial success and specialist management. | Limits indiscriminate growth but supports clinically structured adoption where outcomes justify cost. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global spinal cord stimulation devices market landscape.
24LifeScience develops spinal cord stimulation devices market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. Clinical and access evidence is checked against CDC, NICE, FDA, SEC filings and current primary manufacturer communications. Company status is updated for completed acquisitions so former standalone entities are not presented as independent current competitors.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 2.76 billion in 2025 and is estimated at USD 2.95 billion in 2026. It is projected to reach USD 5.05 billion by 2034 at a 6.9% CAGR during 2026–2034.
It is an implanted neuromodulation system that delivers electrical stimulation through epidural leads to modify chronic pain signaling. A system typically includes an implantable pulse generator, leads, clinician programming equipment and a patient controller.
Rechargeable SCS systems hold the leading position because they are suited to long-duration therapy and can avoid battery-depletion replacement surgery when patients can manage regular charging.
North America is the largest regional market, supported by specialist pain-management infrastructure, reimbursement, major manufacturer presence and rapid access to advanced neuromodulation technologies.
SCS is used for selected chronic intractable pain conditions, including persistent neuropathic pain and post-surgical pain populations, subject to device labeling, clinical assessment and local reimbursement rules.
CDC reported that 24.3% of U.S. adults had chronic pain in 2023 and 8.5% had high-impact chronic pain. SCS is appropriate only for a selected subset after appropriate clinical evaluation.
Key developments include high-frequency and burst stimulation, ECAP-based closed-loop sensing, automated programming, smaller rechargeable implants, digital follow-up tools and broader MR-conditional labeling.
Globus Medical completed its acquisition of Nevro on April 3, 2025. Nevro became a wholly owned subsidiary of Globus Medical, so the competitive landscape is presented on that current basis.
The current competitive set includes Medtronic, Boston Scientific, Abbott, Globus Medical through Nevro, Saluda Medical and Nalu Medical.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
